Market Highlights:

Global Vulvar Cancer Market Research Report: Information by Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Biologic Therapy), End User (Hospitals Clinics, Research Academic Institutes, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East Africa)—Forecast till 2027

Vulvar cancer is squamous cell skin cancer that occurs in elderly women. It is one of the rare type of cancer and the 4th common gynecologic cancer. Human papillomavirus infection, vulvar intraepithelial neoplasia, heavy cigarette smoking and many other things are major risk factors for this diseases. Beside these women suffering from HIV are also prone to develop vulvar cancer. The major driving factor for this market are increasing prevalence of vulvar cancer, continuous improvement in technology, growing consumer awareness and government’s initiatives. While high cost, availability of HPV vaccines and side effect of the therapy are the major restraining factor for the growth of this market.

As per region global vulvar cancer market is segmented into North America, Europe, Asia Pacific along with Middle East and Africa. Due to increasing prevalence of cancer, growing technological development and improvement in treatment all these are responsible for making the North American vulvar cancer market as the largest market. Europe is the second largest market followed by Asia Pacific. Due to continuous development in the healthcare sector and continuously growing population all these has led to growth of this market in Asia Pacific region.

The global vulvar cancer market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 681.85 million in 2018 and is projected to register a 6.2% CAGR over the forecast period.

Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1423

Segmentation:

Global vulvar cancer market is segmented on the basis of types which includes adenocarcinoma, squamous cell carcinomas, melanoma, sarcoma and other. On the basis of treatment the market is segmented into radiation therapy, chemotherapy, surgery and drugs treatment. Surgery is further sub segmented into excision, radical vulvectomy, partial vulvectomy and other. On the basis of end user it is segmented into hospitals, clinics, cancer research institutes and other

On application, chemotherapy is the most preferred treatment for vulvar cancer. However, due to side effects this segment may have slow growth and its position will be taken by surgical treatment.

Competitive Analysis:

There are many players in the global vulvar cancer market, some of the key players are Abbott Diagnostics (US), Ono Pharmaceutical co ltd (Japan), PDS Biotechnology Corporation (US), Becton Deckinson and Company (US), Siemens Healthcare (Germany), Qiagen (Germany), ISA Pharmaceuticals B.V. (Netherland), ORYX GmbH Co. KG (Germany), PfizerInc(US), AmgenInc.(US), Johnson Johnson (US), Novartis AG (Switzerland),F. Hoffmann-La Roche Ltd (Switzerland), Celgene Corporation (US), MerckCo.(US) and many more.

Due to increasing prevalence of vulvar cancer, globally many companies are in the race of inventing better treatment for vulvar cancer. Companies are using a trend of strategic alliance and acquisition to gain a high position in the market and minimize competition in the market.

Ono pharmaceutical co ltd, in 2017 has announced results of phase ½ clinical trial of opdivo (nivolumab). This drug has shown to give better results to patients who are suffering from vulvar cancer.

PDS Biotechnology Corporation, a biotechnological company is working on the development of new drug PDS0101 which is used for the treatment of vulvar cancer. In 2016, the company had submitted results obtained from phase I/IIA clinical study of PDS0101. The study had shown a strong position for this drug which has given a superior disease-specific T-cell response.

Qiagen, a provider of sample and assay technologies for molecular diagnostics, testing and pharmaceutical research. This company has introduce new in vitro method for detecting human papillomavirus which causes vulvar cancer.

Novartis AG, a Swiss headquartered company has introduced Oncofocus®. Oncofocus® which is the oncology test used for detection of type of cancer and is considered as world’s most comprehensive precision oncology test which increases the chances of successful treatment.

Merck Co. one of the leading pharmaceutical and research company has introduced Gardasil. This vaccine is approved by FDA for the treatment of vaginal and vulvar cancer. This vaccine is considered as the major achievement in the treatment of cancer.

Table Of Contents:

REPORT PROLOGUE

MARKET INTRODUCTION

2.1. Definition

2.2. Scope Of The Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

MARKET FACTOR ANALYSIS

Continue....

Browse Complete Report @ https://www.marketresearchfuture.com/reports/vulvar-cancer-market

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]